210 related articles for article (PubMed ID: 17961046)
1. Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition.
Gupta V; Samuleson CG; Su S; Chen TC
Neurosurg Focus; 2007; 23(4):E9. PubMed ID: 17961046
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas.
Gupta V; Su YS; Samuelson CG; Liebes LF; Chamberlain MC; Hofman FM; Schönthal AH; Chen TC
J Neurosurg; 2007 Mar; 106(3):455-62. PubMed ID: 17367069
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
[TBL] [Abstract][Full Text] [Related]
4. Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells.
Al-Khalaf HH; Lach B; Allam A; Hassounah M; Alkhani A; Elkum N; Alrokayan SA; Aboussekhra A
Brain Res; 2008 Jan; 1188():25-34. PubMed ID: 18048012
[TBL] [Abstract][Full Text] [Related]
5. Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro.
Ragel BT; Gillespie DL; Kushnir V; Polevaya N; Kelly D; Jensen RL
Neurosurgery; 2006 Nov; 59(5):1109-20; discussion 1120-1. PubMed ID: 17143245
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.
Horak P; Wöhrer A; Hassler M; Hainfellner J; Preusser M; Marosi C
J Neurooncol; 2012 Sep; 109(2):323-30. PubMed ID: 22610940
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
Schrell UM; Rittig MG; Anders M; Kiesewetter F; Marschalek R; Koch UH; Fahlbusch R
J Neurosurg; 1997 May; 86(5):845-52. PubMed ID: 9126901
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.
Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
Cancer; 2007 Feb; 109(3):588-97. PubMed ID: 17177201
[TBL] [Abstract][Full Text] [Related]
10. Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.
Kondraganti S; Gondi CS; Gujrati M; McCutcheon I; Dinh DH; Rao JS; Olivero WC
Int J Oncol; 2006 Jul; 29(1):25-32. PubMed ID: 16773181
[TBL] [Abstract][Full Text] [Related]
11. Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.
Skibinski CG; Williamson T; Riggins GJ
J Neurooncol; 2018 Dec; 140(3):529-538. PubMed ID: 30414098
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo.
Matsuda Y; Kawamoto K; Kiya K; Kurisu K; Sugiyama K; Uozumi T
J Neurosurg; 1994 Mar; 80(3):527-34. PubMed ID: 8113866
[TBL] [Abstract][Full Text] [Related]
13. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells.
Kliese N; Gobrecht P; Pachow D; Andrae N; Wilisch-Neumann A; Kirches E; Riek-Burchardt M; Angenstein F; Reifenberger G; Riemenschneider MJ; Meese E; Panayotova-Dimitrova D; Gutmann DH; Mawrin C
Oncogene; 2013 Sep; 32(39):4712-20. PubMed ID: 23108408
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Reardon DA; Norden AD; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Sampson JH; Gururangan S; Peters KB; McLendon RE; Norfleet JA; Lipp ES; Drappatz J; Wen PY; Friedman HS
J Neurooncol; 2012 Jan; 106(2):409-15. PubMed ID: 21938530
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
[TBL] [Abstract][Full Text] [Related]
16. mTORC1 inhibitors suppress meningioma growth in mouse models.
Pachow D; Andrae N; Kliese N; Angenstein F; Stork O; Wilisch-Neumann A; Kirches E; Mawrin C
Clin Cancer Res; 2013 Mar; 19(5):1180-9. PubMed ID: 23406776
[TBL] [Abstract][Full Text] [Related]
17. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
Jiang C; Song T; Li J; Ao F; Gong X; Lu Y; Zhang C; Chen L; Liu Y; He H; Huang O
Mol Neurobiol; 2017 Jan; 54(1):779-787. PubMed ID: 27021020
[TBL] [Abstract][Full Text] [Related]
18. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
Palmberg E; Johnsen JI; Paulsson J; Gleissman H; Wickström M; Edgren M; Ostman A; Kogner P; Lindskog M
Int J Cancer; 2009 Mar; 124(5):1227-34. PubMed ID: 19058199
[TBL] [Abstract][Full Text] [Related]
19. The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
Wilisch-Neumann A; Kliese N; Pachow D; Schneider T; Warnke JP; Braunsdorf WE; Böhmer FD; Hass P; Pasemann D; Helbing C; Kirches E; Mawrin C
Clin Cancer Res; 2013 Oct; 19(19):5402-12. PubMed ID: 23948974
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application.
Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
J Neurosurg; 2005 Sep; 103(3):508-17. PubMed ID: 16235684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]